FDA APPROVES NEW CARDIAC DEVICE: DRISCOLL IS FIRST & ONLY IN SOUTH TEXAS
TO OFFER New technology and training offers less
invasive procedure (Corpus Christi, TX) The Food and Drug Administration (FDA) recently approved device for percutaneous closure of muscular Ventricular Septal Defect (mVSD), a congenital heart defect. With the approval, Driscoll Children’s Hospital is the first and only facility in South Texas to offer a non-surgical closure of the muscular VSD for pediatric patients. The new VSD closure procedure is performed by a specially trained pediatric cardiologist with a team of nurses and technicians, in the hospital’s catheterization laboratory, thus avoiding an open-heart surgical procedure. Patients benefit from a shorter hospital stay and recovery time, fewer complications, and less chance of infection and bleeding. Most patients resume normal activities within a few days following the procedure. Prior to the approval, Driscoll performed this procedure in emergent situations only on compassionate basis. “Our continuous commitment is to provide the best for our children
through quality healthcare,” says Steve Woerner, President and C.E.O.
of Driscoll. “This state-of-the-art technology and training will
benefit our patients with a shorter hospital stay and recovery.” Ventricular septal defect (VSD) is the most common congenital heart defect and is a hole in the heart’s wall that separates the two lower chambers. The opening allows for increased blood flow and forces the heart to work harder than normal. Patients with VSD can become easily fatigued, have difficulty breathing, fail to grown normally, and be susceptible to colds, pneumonia, and other infectious diseases. If left untreated, VSD can lead to heart arrhythmias, heart failure, high blood pressure, stroke, and even death. Traditionally, VSD was repaired through open heart surgery, requiring incisions through the breastbone and heart muscle, followed by sewing a patch over the larger defects or stitches in the smaller defects, restoring normal blood circulation. A flexible, hour glass plug made of a nitinol (nickel and titanium alloy) wire mesh is placed in the heart through a small catheter from the groin vessel. It contracts into the catheter and expands once it’s in the hole. Once in position, the device is released where tissue will grow over the device within three to six months. Driscoll has been performing device closure of atrial septal defect (ASD),
a less complicated but similar procedure, for approximately five years.
www.driscollchildrens.org # # #
Home
| Terms of Use
| Privacy
Policies | Legal
Statement
|